Subacute administration of sodium periodate via oral gavage resulted in a cascade of effects that were secondary to kidney toxicity. Decreased mass of ovaries and epididymides and testicular degeneration were observed in sodium periodate groups with signs of kidney toxicity. These groups also exhibited decreased T3 and T4 in the presence of decreased TSH, a pattern associated with uremia. Sodium periodate exposed rats exhibited both activation of the innate immune system and lymphocyte depletion; however, the pattern of effects was more indicative of a stress leukogram. Effects on the thymus and spleen in the absence of adrenal hyperplasia suggest more direct effects on the immune system. Decreased body mass observed in high dose groups was associated with gross and histopathologic findings in the gastrointestinal tract and may be related to effects on absorption. Increased cholesterol was identified as the critical endpoint and was used to derive the BMDL10s of 17.2 and 33.7 mg/kg-day for females and males, respectively. oral toxicity, explosives, insensitive munitions, sodium periodate, thyroid, uremia
REPORT DOCUMENTATION PAGEThe public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information , 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)2. REPORT TYPE 3. DATES COVERED (From -To) 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER 5b. GRANT NUMBER 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER
SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
SPONSOR/MONITOR'S REPORT NUMBER(S)12
Good Laboratory Pract ice Compliance StatementThe study described in this report was conducted in compliance with Title 40, Code of Federal Regulations (CFR), Part 792, Good Laboratory Practice Standards, except for the following:1. The test article characterization (purity) was conducted by the manufacturer and it is not known whether the testing was done in compl iance with the above regulation.2. The concentrations of the test article dosing suspensions/solutions for the acute portion of the study were not verified analytically in accordance with Good Laboratory Practice Standards. The a...